Scientific Research into Medicinal Cannabis – IBD Inflammatory Bowel Disease
Inflammatory Bowel Disease is a term mainly used to describe two conditions: ulcerative colitis and Crohn’s disease.
Ulcerative colitis and Crohn’s disease are long-term conditions that involve inflammation of the gut. Ulcerative colitis only affects the colon (large intestine). Crohn’s disease can affect any part of the digestive system, from the mouth to the anus.
We have listed the latest scientific research into medicinal cannabis and it’s potential uses treating Inflammatory Bowel Disease (IBD)
- Cannabidiol in inflammatory bowel diseases: A brief overview
- CBD reduces intestinal inflammation through the control of neuroimmune axis
- Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
- Cannabinoid actions at TRPV channels: Effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation
- Therapeutic potential of cannabinoid-based drugs
- Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease (Biochemical Pharmacology)
- CBD and the gut: New developments and emerging concepts
- Endocannabinoids and the gastrointestinal tract
- CBD and gastrointestinal motility
- Getting into the weed: the role of the endocannabinoid system in the brain-gut axis
- Cannabinoids and GI Disorders: Endogenous and Exogenous